Neovascularization Potential of Blood Outgrowth Endothelial Cells From Patients With Stable Ischemic Heart Failure Is Preserved

Abstract

BackgroundBlood outgrowth endothelial cells (BOECs) mediate therapeutic neovascularization in experimental models, but outgrowth characteristics and functionality of BOECs from patients with ischemic cardiomyopathy (ICMP) are unknown. We compared outgrowth efficiency and in vitro and in vivo functionality of BOECs derived from ICMP with BOECs from age‐matched (ACON) and healthy young (CON) controls.Methods and ResultsWe isolated 3.6±0.6 BOEC colonies/100×106 mononuclear cells (MNCs) from 60‐mL blood samples of ICMP patients (n=45; age: 66±1 years; LVEF: 31±2%) versus 3.5±0.9 colonies/100×106 MNCs in ACON (n=32; age: 60±1 years) and 2.6±0.4 colonies/100×106 MNCs in CON (n=55; age: 34±1 years), P=0.29. Endothelial lineage (VEGFR2+/CD31+/CD146+) and progenitor (CD34+/CD133−) marker expression was comparable in ICMP and CON. Growth kinetics were similar between groups (P=0.38) and not affected by left ventricular systolic dysfunction, maladaptive remodeling, or presence of cardiovascular risk factors in ICMP patients. In vitro neovascularization potential, assessed by network remodeling on Matrigel and three‐dimensional spheroid sprouting, did not differ in ICMP from (A)CON. Secretome analysis showed a marked proangiogenic profile, with highest release of angiopoietin‐2 (1.4±0.3×105 pg/106 ICMP‐BOECs) and placental growth factor (5.8±1.5×103 pg/106 ICMP BOECs), independent of age or ischemic disease. Senescence‐associated β‐galactosidase staining showed comparable senescence in BOECs from ICMP (5.8±2.1%; n=17), ACON (3.9±1.1%; n=7), and CON (9.0±2.8%; n=13), P=0.19. High‐resolution microcomputed tomography analysis in the ischemic hindlimb of nude mice confirmed increased arteriogenesis in the thigh region after intramuscular injections of BOECs from ICMP (P=0.025; n=8) and CON (P=0.048; n=5) over vehicle control (n=8), both to a similar extent (P=0.831).Conclusions BOECs can be successfully culture‐expanded from patients with ICMP. In contrast to impaired functionality of ICMP‐derived bone marrow MNCs, BOECs retain a robust proangiogenic profile, both in vitro and in vivo, with therapeutic potential for targeting ischemic disease.

Transplantation of Endothelial Progenitor Cells Overexpressing miR-126-3p Improves Heart Function in Ischemic Cardiomyopathy

“…4 There is growing evidence that endothelial progenitor cells (EPCs) are involved in myocardial angiogenesis of ICM patients. 5 However, in contrast to EPCs from healthy subjects, the transplantation of EPCs from CHF patients failed to increase angiogenesis. This reveals that impaired EPC angiogenesis occurs in CHF patients.…”

IFN‐γ enhances the wound healing effect of late EPCs (LEPCs) via BST2‐mediated adhesion to endothelial cells

“…It has been reported that LEPCs play a role in wound healing, with the greatest angiogenic potential . Clinical studies have also shown that LEPCs improve vascular outcomes in ischemic and chronic wound patients .…”

“…After homing, activated LEPCs initiate adhesion to vascular endothelial cells (ECs). In sequence, transendothelial migration into the sites of the wounded endothelium and differentiation into mature ECs proceed . Throughout this process, LEPCs promote endothelial remodeling and wound healing by supplying neovasculature.…”

“…Clinical interest has been focused on therapeutic angiogenesis by injecting ex vivo expanded LEPCs into patients. Various clinical studies have shown improved vascular outcomes in patients with ischemic and chronic wounds . However, one of the major challenges for this approach is that a low number of intravenously injected LEPCs reach the site of diseased target area due to their circulatory nature and low adhesion rate .…”

Endothelial Progenitor Cells Dysfunction in Diabetes Mellitus

“…There is evidence regarding potent possibilities to improve the EPCs' capacity using various methods, i.e. aerobic exercise, lipid lowering drugs, ACE inhibitors, calcium channel blockers, antidiabetic drugs including metformin, sitagliptin [71][72][73][74][75]. Several mechanisms are involved in the attenuation of EPCs functionality by mentioned above approaches, i.e.…”